Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein

[1]  C. King,et al.  Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages , 2019, Malaria Journal.

[2]  S. Sirima,et al.  Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers , 2019 .

[3]  H. Wardemann,et al.  Antibodies against Plasmodium falciparum malaria at the molecular level , 2019, Nature Reviews Immunology.

[4]  Dagmar Hartge,et al.  Report , 2019, Datenschutz und Datensicherheit - DuD.

[5]  A. Lanzavecchia,et al.  The Antibody Response to Plasmodium falciparum: Cues for Vaccine Design and the Discovery of Receptor-Based Antibodies. , 2019, Annual review of immunology.

[6]  Photini Sinnis,et al.  Important Extracellular Interactions between Plasmodium Sporozoites and Host Cells Required for Infection. , 2019, Trends in parasitology.

[7]  M. Tanner,et al.  RTS,S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials , 2018, Trials.

[8]  I. Wilson,et al.  Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts , 2018, Science Advances.

[9]  B. Ramakrishnan,et al.  Extending human IgG half-life using structure-guided design , 2018, mAbs.

[10]  A. Pain,et al.  A fast and cost-effective microsampling protocol incorporating reduced animal usage for time-series transcriptomics in rodent malaria parasites , 2018, Malaria Journal.

[11]  S. Hoffman,et al.  Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope , 2018, Science.

[12]  S. Kappe,et al.  Humanized Mouse Models for the Study of Human Malaria Parasite Biology, Pathogenesis, and Immunity , 2018, Front. Immunol..

[13]  Alex B. Miller,et al.  Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite , 2018, Nature Medicine.

[14]  Alex B. Miller,et al.  A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite , 2018, Nature Medicine.

[15]  S. Hoffman,et al.  A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein , 2018, Nature Medicine.

[16]  S. Hoffman,et al.  Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection , 2018, The Journal of experimental medicine.

[17]  S. Kappe,et al.  Natural Parasite Exposure Induces Protective Human Anti‐Malarial Antibodies , 2017, Immunity.

[18]  A. Bradley,et al.  Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25 , 2017, Nature Communications.

[19]  I. Wilson,et al.  Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein , 2017, Proceedings of the National Academy of Sciences.

[20]  Erika L. Flannery,et al.  Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice , 2017, npj Vaccines.

[21]  A. Hill,et al.  Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine , 2017, Scientific Reports.

[22]  D. Christensen,et al.  Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection , 2017, npj Vaccines.

[23]  Paige E. Waterman,et al.  Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. , 2016, The Journal of infectious diseases.

[24]  Juliana K. Wambua,et al.  Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. , 2016, The New England journal of medicine.

[25]  Kwaku Poku Asante,et al.  Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial , 2015 .

[26]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[27]  A. Vaughan,et al.  Model for In Vivo Assessment of Humoral Protection against Malaria Sporozoite Challenge by Passive Transfer of Monoclonal Antibodies and Immune Serum , 2013, Infection and Immunity.

[28]  Mario Roederer,et al.  Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine , 2013, Science.

[29]  C. Ockenhouse,et al.  Development of a Chimeric Plasmodium berghei Strain Expressing the Repeat Region of the P. vivax Circumsporozoite Protein for In Vivo Evaluation of Vaccine Efficacy , 2013, Infection and Immunity.

[30]  Photini Sinnis,et al.  The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host , 2011, The Journal of experimental medicine.

[31]  V. Nussenzweig,et al.  From the circumsporozoite protein to the RTS,S/AS candidate vaccine , 2010, Human vaccines.

[32]  David Firth,et al.  Bias reduction in exponential family nonlinear models , 2009 .

[33]  Kurt Hornik,et al.  Implementing a Class of Permutation Tests: The coin Package , 2008 .

[34]  S. Levy,et al.  Expression of human CD81 differently affects host cell susceptibility to malaria sporozoites depending on the Plasmodium species , 2006, Cellular microbiology.

[35]  Torsten Hothorn,et al.  On the Exact Distribution of Maximally Selected Rank Statistics , 2002, Comput. Stat. Data Anal..

[36]  V. Nussenzweig,et al.  Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. , 1985, Science.

[37]  Samy Suissa,et al.  Exact unconditional sample sizes for the 2×2 binomial trial , 1985 .

[38]  D. Waud.  Analysis of dose-response curves , 1981 .